Indication
Neuromyelitis optica
1 clinical trial
1 drug
Clinical trial
Single-center, Open Label Trial of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active Neuromyelitis Optica Spectrum Disorders (NMOSD)Status: Completed, Estimated PCD: 2018-02-15
Drug
Tocilizumab